Condition: Hepatocellular Carcinoma (HCC) · Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
This is a single-arm, open-label study of safety, tolerability, and anti-cancer activity of SN301A (an off-the-shelf CAR NK cell therapy) in patients with glypican-3 (GPC3)-positive advanced hepatocellular carcinoma.
This description comes directly from the study's public registry record.
Qi Li, MD · 86-021-60524213 · Leeqi2001@hotmail.com
Jingyi Zhou, MD · 86-021-60524213 · jingyi_zhou9468@163.com
Always discuss trial participation with your own doctor first.
| Shanghai General Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06652243